On Apr. 7, 2020, Mesa Biotech announced it was shipping 10,000 of its Accula SARS-CoV-2 molecular rapid point of care (POC) tests. The company’s COVID-19 test uses patented technology to enable ‘near patient’ testing outside of the central laboratory with diagnostic results in 30 minutes.

The Accula SARS-CoV-2 is easy to use, fits in the palm of your hand and provides a highly accessible means for healthcare professionals to access laboratory quality results near the patient.